Company intelligence / Profile preview

Vanarix

Lausanne, Vaud, Switzerlandvanarix-cartilage-regeneration.ch ↗

Ownership: Private
Development stage: Phase 1

Overview

Vanarix has completed recruitment for a First-In-Man study with Autologous Cartibeads™ that began in 2022, with preliminary data indicating initial safety and efficacy in treating knee cartilage lesions. A First-In-Man study for Allogeneic Cartibeads™ is ongoing, with recruitment expected to be completed in 2024[1]. In December 2022, they reported their first successful transplantation[5]. In January 2025, Vanarix obtained Orphan Disease Designation from the FDA[5].

Therapeutic areas: Rheumatology
Modalities: Cell therapyTissue engineering
Industry: Biotech

Drug pipeline

2 assets

allogeneic cartibeads

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Vanarix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vanarix.

Explore the full profile